Levomilnacipran Hydrochloride

盐酸左米那普仑

Report date: 2025/12/02 20:00:12
NME

Base Information

Drug NameLevomilnacipran Hydrochloride
Drug Alias Name左米那普仑Levomilnacipran SR盐酸左旋体米那普仑LevomilnacipranumDextromilnacipran +[8
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin transporter inhibitorsNorepinephrine transporter inhibitors
TargetsNorepinephrine transporterSerotonin transporter
Therapy Area/IndicationsIschemic StrokeDepressive Disorder, MajorDepression
Global Approved IndicationsDepressive Disorder, Major
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2013/07/25
Country/TerritoryCzechiaBelgiumCanada +[14
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesForest Laboratories Inc
China Registration ClassN/A

Develop Information

Active IndicationsDepressive Disorder, Major
Inactive IndicationsIschemic StrokeDepression

Other Information

ATC CodeN06AX